AU Stock MarketDetailed Quotes
IMM Immutep Ltd
- 0.345
- +0.010+2.99%
20min DelayNot Open Dec 27 16:00 AET
501.83MMarket Cap-9.58P/E (Static)
0.350High0.340Low1.12MVolume0.345Open0.335Pre Close387.58KTurnover0.48552wk High0.09%Turnover Ratio1.45BShares0.23052wk Low--EPS TTM431.47MFloat Cap9.000Historical HighLossP/E (Static)1.25BShs Float0.050Historical Low-0.036EPS LYR2.99%Amplitude--Dividend TTM2.65P/B1Lot Size--Div YieldTTM
About Immutep Ltd Company
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
Company Profile
SymbolIMM
Company NameImmutep Ltd
Founded1987
MarketASX
Employees44
Fiscal Year Ends06-30
Address264 George Street Level 32, Australia Square
CitySydney
CountryAustralia
Zip Code2000
Phone+61 283157003
Websitehttps://www.immutep.com
Share RegistryBOARDROOM PTY LIMITED
LEVEL 8, 210 GEORGE STREET, SYDNEY, NSW, AUSTRALIA, 2000
(02) 9290 9600
Company Executives
- Name
- Position
- Salary
- Marc Voigt
- Director, Chief Executive Officer and Chief Financial Officer
- 1.06M
- Professor Dr. Frederic Triebel, M.D.
- Executive Director and Chief Scientific Officer
- 864.44K
- Dr. Florian Vogl, M.D.,PhD
- Chief Medical Officer
- 955.82K
- Deanne Miller
- Chief Operating Officer, General Counsel and Company Secretary
- 565.23K
- Pete A. Meyers
- Deputy Chairman of the Board
- 138.71K
- Dr. Russell J. Howard, PhD
- Chairman of the Board
- 222.02K
- Lis Boyce
- Independent Director
- 144.76K
Heat List
AU
Overall
Symbol
Price
% Chg
No Data
